To assess the performance of the GenoType MTBDR v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial. Direct sputum MTBDR results in the site laboratories were compared to indirect phenotypic drug susceptibility testing (pDST) results in the central laboratory, with DNA sequencing as a reference standard. Of 413 multidrug-resistant TB (MDR-TB) patients tested using MTBDR and pDST, 389 (94.2%) were FQ-susceptible and 7 (1.7%) FQ-resistant, while 17 (4.1%) had an inconclusive MTBDR result. For SLI, 372 (90.1%) were susceptible, 5 (1.2%) resistant and 36 (8.7%) inconclusive. There were 9 (2.3%) FQ discordant pDST/MTBDR results, of which 3 revealed a mutation and 5 (1.3%) SLI discordant pDST/MTBDR results, none of which were mutants on sequencing. Among the 17 FQ- and SLI MTBDRinconclusive samples, sequencing showed 1 FQ- and zero SLI-resistant results, similar to frequencies among the conclusive MTBDR. The majority of inconclusive MTBDR results were associated with low bacillary load samples (acid-fast bacilli smear-negative or scantily positive) compared to conclusive results ( < 0.001). MTBDR can facilitate the rapid exclusion of FQ and SLI resistances for enrolment in clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614701 | PMC |
| http://dx.doi.org/10.5588/ijtld.21.0212 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Accuracy of FluoroCycler XT MTBDR Assay for Detection of Rifampicin and Isoniazid-resistant Mycobacteria tuberculosis in Clinical Isolates from Kenya.
Int J Mycobacteriol
July 2024
National Tuberculosis Reference Laboratory, National Public Health Laboratories, Nairobi, Kenya.
Background: Drug-resistant tuberculosis (DR-TB) poses a major global challenge to public health and therapeutics. It is an emerging global concern associated with increased morbidity and mortality mostly seen in the low- and middle-income countries. Molecular techniques are highly sensitive and offer timely and accurate results for TB drug resistance testing, thereby positively influencing patient management plan.
View Article and Find Full Text PDFDual-centre evaluation of the FluoroType MTBDR version 2 assay for detection of Mycobacterium tuberculosis complex and resistance-conferring mutations in pulmonary and extrapulmonary samples from Denmark, Germany and Sierra Leone.
Clin Microbiol Infect
August 2024
National and WHO Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Objectives: We evaluated the ability of FluoroType MTBDR version 2 (FTv2; Hain Lifescience), a second-step real-time PCR assay, to simultaneously detect Mycobacterium tuberculosis complex (MTBC) DNA and mutations conferring resistance to rifampicin (RIF) and isoniazid (INH), in pulmonary and extrapulmonary samples from patients and compared them with corresponding cultures.
Methods: FTv2 MTBC was evaluated on 1815 and 432 samples from Denmark (DK) and Germany (DE), respectively. RIF and INH resistance mutations were assessed in the German samples and 110 samples from Sierra Leone and subsequently compared to phenotypic antimicrobial susceptibility testing and a composite reference DNA (CRD) based on the GenoType MTBDR line-probe assay and Sanger sequencing or whole-genome sequencing.
The Detection of Mutations and Genotyping of Drug-Resistant Strains Isolated from Patients in the Rural Eastern Cape Province.
Infect Dis Rep
July 2023
Department of Laboratory Medicine and Pathology, Walter Sisulu University, Mthatha 5099, South Africa.
Drug-resistant tuberculosis (DR-TB) is still a major public health concern in South Africa. Mutations in can cause varying levels of phenotypic resistance to anti-TB medications. There have been no prior studies on gene mutations and the genotyping of DR-TB in the rural Eastern Cape Province; hence, we aimed to identify DR-TB mutations, genetic diversity, and allocated lineages among patients in this area.
View Article and Find Full Text PDFIntroduction: Multi-drug-resistant tuberculosis (MDR-TB) has become a major public health concern globally. Mutations in first- and second-line drug targets such as katG, inhA, rpoB, rrs, eis, gyrA, and gyrB have been associated with drug resistance. Monitoring predominant mutations in the MDR-TB patient population is essential to monitor and devise future therapeutic regimes.
View Article and Find Full Text PDFEvaluation of Xpert MTB/XDR test for susceptibility testing of to first and second-line drugs in Uganda.
medRxiv
April 2023
Makerere University, Department of Medical Microbiology.
Background: Drug-Resistant Tuberculosis (DR-TB) is one of the key challenges toward TB control. There is an urgent need for rapid and accurate drug susceptibility tests (DST) for the most commonly used 1 and 2 line TB drugs.
Design And Methods: In a blinded, laboratory-based cross-sectional study, we set out to validate the performance of the Xpert MTB/XDR test for DST of .
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!